Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diacerein for Uncontrolled Type 2 Diabetes
NCT06912035Phase 3Completed
- Sponsor
- Universitas Sriwijaya
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Diacerein with Placebo (2 arms). Primary endpoints: Interleukin-1beta levels at 12 weeks, High-sensitivity C-reactive protein levels at 12 weeks and 2 more. Started Jun 2024; status: completed.
02
Drugs
diacerein
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06912035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912035.